News
06-02-2015, 06:00 AM
AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers.
More... (http://www.news-medical.net/news/20150602/Phase-2-results-from-Abbviee28099s-veliparib-study-in-NSCLC-presented-at-ASCO-2015.aspx)
More... (http://www.news-medical.net/news/20150602/Phase-2-results-from-Abbviee28099s-veliparib-study-in-NSCLC-presented-at-ASCO-2015.aspx)